Shares of Trevi Therapeutics jumped 13.10%, or $2.27, to $19.64 in Friday morning trading, as investor attention turned to the clinical-stage biopharmaceutical company’s presence at a major European medical conference focused on chronic cough treatment.

The New Haven, Connecticut-based company has had representatives at the European Respiratory Society’s Cough Conference in London this week, running from Wednesday through Friday. Trevi Chief Executive Jennifer Good and Chief Development Officer James Cassella have been presenting the company’s clinical trial results for Haduvio, its lead investigational therapy, at the conference, discussing findings the company says demonstrate the drug’s advantages in treating chronic cough associated with several difficult-to-manage lung conditions.

Haduvio, an oral extended-release formulation of nalbuphine, is being developed by Trevi to treat chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, as well as chronic cough associated with non-IPF interstitial lung disease and refractory chronic cough, a condition that persists without an identifiable underlying cause. According to the company, Haduvio is the first and only investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials spanning both IPF-related chronic cough and refractory chronic cough populations. The drug works by acting on the cough reflex pathway both centrally and peripherally, functioning as what the company describes as a kappa agonist and mu antagonist, targeting opioid receptors involved in regulating the chronic cough response.

Trevi’s presentation in London builds on data from its Phase 2b CORAL trial, which evaluated nalbuphine extended-release specifically in patients with IPF-related chronic cough. Primary and subgroup analyses from that trial, including breakdowns by baseline cough count and background use of anti-fibrotic medications, were previously accepted for oral presentation at the American Thoracic Society’s 2026 International Conference earlier this year, underscoring the growing scientific interest in the trial’s results as Trevi works toward advancing Haduvio through additional pivotal studies.

The company has described chronic cough associated with IPF and non-IPF interstitial lung disease as a substantial and underserved market opportunity, citing an estimated 140,000 patients in the United States affected by the condition. Trevi has positioned Haduvio as potentially the only investigational therapy currently addressing this specific unmet medical need with meaningful commercial potential, with the company’s own investor materials pointing to peak sales potential across its target indications reaching as high as $6 billion if the drug successfully advances through further clinical trials and regulatory review.

Friday’s share price jump adds to a volatile but generally upward trajectory for Trevi’s stock so far this year. The stock’s 52-week range spans from a low of $6.50 to a high of $20.15, reflecting a dramatic run-up in valuation over the past twelve months as clinical trial data and analyst coverage have accumulated. As of Friday’s trading, shares remained just below that 52-week high, putting the stock within striking distance of a new record.

Wall Street analysts have generally maintained a bullish stance on the company. According to data compiled by Public.com, ten analysts covering the stock have arrived at a consensus Strong Buy rating as of early July, with an average price target of $21.10. Individual analyst targets have varied more widely: Morgan Stanley raised its price target on Trevi to $20 from $18 following the company’s first-quarter results in May while maintaining an Overweight rating, and Clear Street lifted its target to $29 from $21 earlier in May. Additional coverage from firms including Stifel Nicolaus and H.C. Wainwright has similarly maintained Buy ratings on the stock in recent weeks, according to data tracked by CNBC.

Trevi has also taken steps this year to strengthen its balance sheet ahead of continued clinical development. The company closed an underwritten stock offering in June that raised net proceeds of approximately $162 million, with underwriters fully exercising their option to purchase additional shares as part of the deal. According to the company, the additional capital extends its expected cash runway into 2030, providing funding through the potential FDA approval of Haduvio for IPF-related chronic cough and supporting continued advancement of the company’s broader pipeline across its other targeted indications.

Not all recent developments have been unambiguously positive for the stock. Trevi Therapeutics was recently removed from several Russell stock indexes, including the Russell 3000E and Russell Microcap index families, as part of a periodic index reshuffling process. Such removals can sometimes trigger forced selling from index-tracking funds, though the stock’s continued strength in recent sessions suggests any technical pressure from the index changes has been outweighed by broader investor enthusiasm tied to the company’s clinical progress and conference presentations.

Trevi’s next major scheduled catalyst is its upcoming earnings report, expected August 6, when the company is likely to provide further updates on the progress of its ongoing Phase 3 trials for Haduvio in IPF-related chronic cough, along with any additional data emerging from this week’s presentations in London. The company was founded in 2011 by Thomas R. Sciascia and Jennifer L. Good and has built its pipeline around nalbuphine-based therapies through a license agreement with Keenova Therapeutics for various formulations of the compound.

With a market capitalization now in the range of $2.5 billion to $2.6 billion, Trevi remains a mid-cap biotechnology name whose valuation continues to hinge heavily on the outcome of its ongoing and upcoming clinical trials rather than existing product revenue, given that Haduvio has not yet received regulatory approval from the U.S. Food and Drug Administration or any other regulatory authority. Some independent analysts have cautioned that the company’s current valuation may not yet fully reflect the risks inherent in bringing a novel therapy through the remaining stages of clinical development and eventual commercial launch, even as the stock has continued climbing on the strength of its trial data and growing analyst support. For now, Friday’s rally reflects renewed investor optimism following the company’s presence at one of the field’s most closely watched medical conferences this year.

A judge on Friday declined to issue a ruling from the bench regarding California’s request for a temporary restraining order freezing Paramount’s planned takeover of Warner Bros. Discovery (WBD) 

Paramount CEO David Ellison is seeking to acquire WBD in a $111 billion deal that was expected to close during the third quarter of this year, but California Attorney General Rob Bonta is leading a group of 12 state attorneys general who filed a lawsuit challenging the merger. The lawsuit claims the megadeal would “lead to higher prices, lower quality, and less content for film and television, harming movie theaters, basic cable distributors, and ultimately, audiences on every sofa and movie theater seat in the U.S.” 

The lawsuit, filed in the U.S. District for the Northern District of California, claims that the merger violates Section 7 of the Clayton Act, which holds that mergers that may substantially lessen competition or tend to create a monopoly are illegal. 

PARAMOUNT ADVISERS PUSH FOR CALIFORNIA EXIT AS STATE SUES TO BLOCK WARNER BROS DISCOVERY MERGER: REPORT

California Attorney General Rob Bonta believes Paramount’s planned takeover of Warner Bros. Discovery is “an illegal merger.”  (AaronP/Bauer-Griffin/GC Images / Getty Images)

A TRO hearing on Friday got deep into antitrust law, with Paramount arguing the merger would actually increase competition while the state insists that combining two major Hollywood studios would hurt the industry while giving too much power to the company. 

District Judge Araceli Martínez-Olguín promised to issue a ruling by July 22. 

Paramount is seeking to move forward as soon as possible to avoid exorbitant ticking fees, a term for charges that accrue as the merger is delayed. Reporters were prohibited from taking photos or video of the hearing.

WARNER BROS DISCOVERY SHAREHOLDERS APPROVE PARAMOUNT SKYDANCE DEAL

California Attorney General Rob Bonta. (Sarah Reingewirtz/MediaNews Group/Los Angeles Daily News via Getty Images / Getty Images)

The Justice Department (DOJ) announced last week it has closed its antitrust investigation into Paramount Skydance’s proposed acquisition of WBD, concluding the transaction is not likely to harm competition or American consumers.

The Antitrust Division said its eight-month review examined more than two million documents and found the deal could strengthen competition across the media and entertainment industry, including in streaming video, traditional television and theatrical film distribution. However, state attorneys general retain independent authority under antitrust laws. 

Ellison, the son of billionaire Oracle co-founder Larry Ellison, took control of Paramount last year when Skydance Media and Paramount Global completed an $8 billion merger. Adding WBD to his portfolio would make the younger Ellison one of Hollywood’s most powerful people.

CALIFORNIA AG BLASTS PARAMOUNT-WBD MERGER AS ‘ILLEGAL,’ SAYS THREAT TO LEAVE STATE IS ‘BLACKMAIL’ EFFORT

Paramount CEO David Ellison. (Charly Triballeau/AFP via Getty Images / Getty Images)

Paramount fired back Monday shortly after the complaint was filed, saying the lawsuit “reflects a fundamentally flawed application of the antitrust laws and is wrong on both the facts and the law.”

“We will vigorously defend the transaction and demonstrate that this challenge is inconsistent with sound competition policy and the competitive realities of the media marketplace. Delaying this transaction will only harm entertainment workers who have already suffered over recent years as technology has disrupted their livelihood and cost California tens of thousands of entertainment jobs,” a Paramount spokesperson said in a statement to Fox News Digital.

“The combination of Paramount and WBD will create a stronger, well-capitalized, creative-first media company that is better positioned to compete with companies like Netflix that have come to dominate the industry for audiences, premium content, and creative talent,” the spokesperson continued. “Put simply, any attempt to block this transaction undermines the very principles antitrust law is designed to promote: more competition, more choice for consumers, and more opportunities for creators and workers.”

CLICK HERE TO GET THE FOX NEWS APP